HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Adjusts Price Target To $19 (1-10 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino maintains a Buy rating on NRX Pharmaceuticals (NASDAQ:NRXP) and adjusts the price target to $19 from $2 following a 1-10 reverse stock split.
August 05, 2024 | 7:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on NRX Pharmaceuticals and adjusts the price target to $19 from $2 following a 1-10 reverse stock split.
The maintenance of a Buy rating and a significant increase in the price target from $2 to $19 by a reputable analyst is likely to positively impact NRXP's stock price in the short term. The 1-10 reverse stock split is also a notable event that could influence investor perception.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100